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Abstract
Small interfering RNAs (siRNAs) are able to silence their target genes when they are successfully
delivered intact into the cytoplasm. Delivery systems that enhance siRNA localization to the
cytoplasm can facilitate gene silencing by siRNA therapeutics. We describe an arginine-conjugated
poly(cystaminebisacrylamide-diaminohexane) (poly(CBA-DAH-R)), a bioreducible cationic
polymer, as an siRNA carrier for therapeutic gene silencing for cancer. After intracellular uptake of
the siRNA/poly(CBA-DAH-R) polyplexes, the reductive environment of the cytoplasm cleaves the
disulfide linkages in the polymeric backbone, resulting in decomplexing of the siRNA/poly(CBA-
DAH-R) polyplexes and release of siRNA molecules throughout the cytoplasm. The siRNA/poly
(CBA-DAH-R) polyplexes, which demonstrate increased membrane permeability with arginine
modification, have a similar level of cellular uptake as siRNA/bPEI polyplexes. The VEGF siRNA/
poly(CBA-DAH-R) polyplexes, however, inhibit VEGF expression to a greater degree than VEGF
siRNA/bPEI in various human cancer cell lines. The improved RNAi activity demonstrated by the
VEGF siRNA/poly(CBA-DAH-R) polyplexes is due to enhanced intracellular delivery and effective
localization to the cytoplasm of the VEGF siRNAs. These results demonstrate that the VEGF siRNA/
poly(CBA-DAH-R) polyplex delivery system may useful for siRNA-based approaches for cancer
therapy.
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Introduction
Synthetic siRNAs, 21–23 nucleotides in length, mediate target gene silencing by promoting
mRNA degradation in the cytoplasm.1 Since many diseases are caused by the inappropriate
expression of disease-related genes, siRNA technology may provide new therapies for the
treatment of diverse human diseases including cancer, obesity, heart disease, and diabetes.2,3
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siRNA therapeutics offer advantages over conventional pharmaceutics because of their
powerful and specific gene silencing ability. The practical applications of siRNAs, however,
have been limited by their instability and poor delivery to the necessary site of action.4 The
development of safe and effective delivery vehicles for siRNAs would greatly enhance the
clinical utility of gene silencing siRNAs as a therapeutic modality for the treatment of cancer.
Various polycations have been developed as nonviral siRNA carriers to enhance the gene
silencing activity of siRNA therapeutics.5,6 Polycations can form highly stable polyelectrolyte
complexes with siRNA molecules via electrostatic interactions between the positively charged
polycations and the negatively charged phosphates of the nucleic acids. These polyelectrolyte
formulations have been shown to improve the protection of siRNA against enzymatic
degradation and increase the cellular uptake efficiency of siRNA.7,8 The latter is important as
sufficient intact, functional siRNA must be localized in the cytoplasm to achieve an effective
intracellular concentration of siRNA to silence the target mRNA.9
Bioreducible cationic polymers containing disulfide linkages arranged regularly on the
polymer backbone structure have been reported to be efficient gene delivery vehicles with
minimal cellular toxicity.10,11 The stable polyelectrolyte complexes composed of bioreducible
cationic polymers and nucleic acids are readily degraded upon exposure to the reductive
environment of the cytoplasm.12,13 This unique characteristic of bioreducible cationic
polymers leads to the release within the cytoplasm of nucleic acids (pDNA and siRNA). Unlike
DNA transfection, delivery to the nucleus is not required for RNAi induction, due to the activity
of siRNA in the cytoplasm. Therefore, polycations which are cleaved upon exposure to a
reductive intracellular state offer the potential for controlled degradation in the cytoplasm,
resulting in safe, high-efficiency siRNA delivery.
We have recently described several branched/linear bioreducible cationic polymers, composed
of low molecular weight cationic monomers and polymerized with disulfide linkages, as
promising gene delivery vehicles.14–16 The bioreducible cationic polymers form stable,
nanosized polyplexes with pDNA and siRNA and achieve higher transfection efficiencies with
significantly less cytotoxicity compared to the conventional cationic polymer: branched
polyethylenimine (bPEI).
To enhance the efficacy of therapeutic gene silencing, we synthesized an arginine-modified
polydisulfide poly(CBA-DAH-R) as an siRNA carrier for cancer gene therapy. Arginine
residues are reported to enhance the cellular membrane permeability of many biologically
active molecules, including drugs, peptides, and plasmids.17–19 The reductive degradation of
the siRNA/poly(CBA-DAH-R) polyplexes was estimated from physicochemical
measurements via dynamic light scattering and gel retardation analysis. The triggered release
characteristics of the siRNA/poly(CBA-DAH-R) polyplexes in correlation with cytoplasmic
siRNA localization and gene knockdown efficiency were investigated in human prostate
carcinoma (PC-3 cells). To verify that poly(CBA-DAH-R) could be a potential siRNA delivery
vehicle for target gene silencing in cancer cells, VEGF gene silencing by the poly(CBA-DAH-
R) polyplexes with VEGF-targeted siRNAs was evaluated in four different human cancer cell
lines (KB, HeLa, A2780, and A549).
Experimental Section
Materials
Branched polyethylenimine (bPEI, Mw 25,000), dithiothreitol (DTT), 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), and DL-buthionine-sulfoxamine
(BSO) were purchased from Sigma-Aldrich (St. Louis, MO). Poly(CBA-DAH-R) was
prepared as shown in the supplemental figure in the Supporting Information. Human VEGF
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siRNA (sense, 5′-GGAGUACCCUGAUGAGAUCdTdT-3′; antisense, 5′-
GAUCUCAUCAGGGUACUCCdTdT-3′) and green fluorescent protein (GFP) siRNA (sense,
5′-GCACGACUUCUUCAAGUCCdTdT-3′; antisense, 5′-
GGACUUGAAGAAGUCGUGCdTdT-3′) were synthesized, modified and purified by
Dharmacon Co. (Lafayette, CO). For flow cytometry and confocal microscopy, siRNA was
labeled with Cy3 dye at the 3′-terminal end of the sense strand. All cell culture products
including fetal bovine serum (FBS), Roswell Park Memorial Institute 1640 medium (RPMI
1640), and Dulbecco’s phosphate buffered saline (PBS) were obtained from Invitrogen (Gibco
BRL, Carlsbad, CA).
Dynamic Light Scattering (DLS) Assay
The siRNA polyplexes with poly(CBA-DAH-R) and bPEI were formed at various weight ratios
(polymer/siRNA) ranging from 10:1 to 60:1 and from 0.1:1 to 60:1, respectively. A fixed
amount of siRNA (3 μg) was complexed with different amounts of polymers (poly(CBA-DAH-
R) or bPEI) in 0.4 mL HEPES buffer (HEPES 20 mM, 5% glucose, pH 7.4). After 30 min
incubation at room temperature, the polyplex solution was 6-fold diluted with deionized water.
To determine the degradation ability of the siRNA/poly(CBA-DAH-R) polyplexes, the siRNA
polyplexes, which were formed with poly(CBA-DAH-R) and bPEI at a weight ratio of 40:1
and 1:1 respectively, were further incubated with 2.5 mM DTT for 2 h at 37 °C. Particle sizes
and surface charges were measured using a Zetasizer 3000HS (Malvern Instrument, Inc.,
Worcestershire, U.K.) at a wavelength of 677 nm with a constant angle of 90 ° at 25 °C.
Electrophoretic Mobility Shift Assay
The siRNA/poly(CBA-DAH-R) polyplexes were prepared at different weight ratios ranging
from 0:1 to 40:1. siRNA (0.3 μg) was condensed with varying amounts of poly(CBA-DAH-
R) in an aqueous phase (PBS 30 μL, pH 7.4) and incubated at room temperature for 30 min.
The siRNA/bPEI polyplexes were formed at a weight ratio of 1:1. Each sample solution was
loaded onto a 2.0% agarose gel. Electrophoresis was carried out with a current of 120 V for
15 min in 1 × TAE buffer solution (10 mM Tris/HCl, 1% (v/v) acetic acid, 1 mM EDTA). The
retardation of the polyplexes was visualized with an image analyzer equipped with a UV
transilluminator (GelDoc, BioRad, Hercules, CA) after ethidium bromide staining. To
characterize the cleavability of poly(CBA-DAH-R) under reductive conditions, the polyplexes
were preincubated with 2.5 mM DTT for 2 h at 37 °C prior to electrophoresis.
Cells and Cell Culture Conditions
Human prostate carcinoma (PC-3), human oral cavity epidermal carcinoma (KB), human
cervical carcinoma (HeLa), human ovarian carcinoma (A2780), and human lung carcinoma
(A549) were obtained from American Type Culture Collection (Manassas, VA). Cells were
routinely maintained in an RPMI 1640 medium supplemented with 10% fetal bovine serum.
Cells were cultured as a monolayer in a humidified atmosphere containing 5% CO2 at 37 °C.
Cells were regularly passaged and reseeded 24 h before transfection experiments.
Cellular Toxicity Assay
Relative cell viability was determined using an MTT (Thiazolyl Blue Tetrazolium Bromide)
assay. PC-3 cells were plated in 96-well plates at a density of 1 × 104 cells per well in 0.2 mL
of culture medium and incubated for 24 h at 37 °C prior to polyplex treatment. The medium
was replaced by a fresh serum-free transfection medium containing a desired amount of the
siRNA polyplexes with poly(CBA-DAH), poly(CBA-DAH-R), and bPEI, which were formed
at different weight ratios from 0:1 to 60:1. The polyplexes were prepared using 0.15 μg of
siRNA and varying amounts of the polymers in 0.1 mL of PBS (pH 7.4). Cells were transfected
by the polyplexes for 4 h at 37 °C and further incubated in a fresh serum-containing medium
Kim et al. Page 3
Mol Pharm. Author manuscript; available in PMC 2009 September 30.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
for 24 h at 37 °C. Fifty microliters of MTT solution (2 mg/mL) were added and incubated at
37 °C for 4 h. The produced formazan crystals were dissolved in 0.2 mL of DMSO followed
by plate reading at 530 nm in a microplate reader (Bio-Rad 680, Hercules, CA). The cell
viability was determined relative to the untreated control cells.
Flow Cytometry and Confocal Microscopy
The cellular uptake of the siRNA polyplexes was examined with flow cytometry and confocal
microscopy by using Cy3 dye-labeled siRNA. The siRNA polyplexes with poly(CBA-DAH),
poly(CBA-DAH-R), and bPEI were used at a weight ratio of 40:1, 40:1, and 1:1, respectively.
At the chosen weight ratios of polymer to siRNA, the corresponding calculated charge ratios
for poly(CBA-DAH), poly(CBA-DAH-R), and bPEI were 43:1, 25:1, and 8:1, respectively.
PC-3 cells were plated in 6-well plates at an initial density of 2.5 × 105 cells per well for flow
cytometry analysis. The siRNA polyplexes were formed with 0.75 μg of Cy3-siRNA and a
desired amount of the polymers in an aqueous buffer solution (PBS 0.1 mL, pH 7.4) for 15
min at room temperature. The Cy3-siRNA formulations, including naked siRNA, siRNA/poly
(CBA-DAH), siRNA/poly(CBA-DAH-R), and siRNA/bPEI polyplexes, were added to the
wells containing a serum-free transfection medium. Prior studies in our laboratory had
demonstrated that the transfection efficiencies for the Cy3-siRNA formulations did not differ
between 4, 8, 12 and 24 h of incubation, and so incubation times of 4 h for the Cy3-siRNA
formulations were used throughout the experiments. After 4 h incubation, cells were washed
four times with cold PBS, harvested by trypsin digestion, and fixed in 75% EtOH solution for
30 min at 4°C. Cells were analyzed on a flow cytometer (FACS Caliber, Becton-Dickinson,
Mountain View, CA) using FL2 channel (Ex. 488 nm/Em. 575 nm). Data were processed using
Windows Multiple Document interface software (WinMDI).
For confocal microscopy, PC-3 cells were seeded in confocal imaging dishes (Glass Bottom
microwells, MatTek Corp., Ashland, MA) at a density of 1 × 104 cells per well. Cells were
preincubated in the presence or absence of 10 mM DL-buthionine-sulfoxamine (BSO), which
causes a significant decrease in the intracellular level of reduced glutathione (GSH), for 24 h
prior to transfection. The siRNA polyplexes, which were prepared by the same method
described above, were transfected for 2 h at 37 °C. The transfection medium was replaced with
a fresh culture medium and the cells were incubated for a further 3 h at 37 °C. The cells were
washed with cold PBS four times and fixed with 0.5% para-formaldehyde solution for 30 min
at 4 °C. The localization of Cy3-labeled siRNA within the cells was visualized by a confocal
laser scanning microscope (Olympus Fluoview FV300, Melville, NY) with a 100× oil-
immersion objective lens using an argon/krypton mixed gas laser (Ex. 568 nm). Three-
dimensional confocal images for the cells were constructed by using Velocity software
(Improvision Inc., Lexington, MA).
In Vitro Transfection
For in vitro transfection studies, 2.5 × 105 cells (PC-3, KB, HeLa, A2780, and A549) per well
were plated in a 6-well plate. After 24 h incubation, the culture medium was replaced by the
transfection medium with or without 10% FBS prior to transfection. To decrease the
intracellular reduction potential, cells were preincubated in the presence or absence of 10 mM
BSO at 37 °C for 24 h prior to transfection. VEGF siRNA (1.5 μg) was condensed with a
desired amount of the polymers in 0.2 mL of PBS. The VEGF siRNA polyplexes were left at
an ambient temperature for 30 min and added into the transfection medium. After 4 h
transfection at 37 °C, the transfection medium was replaced with a fresh medium containing
10% FBS and continuously incubated for a further 8 h. The medium was removed and
supplemented with fresh culture medium containing heparin (20 μg/mL). After 18 h incubation,
the medium was collected for VEGF ELISA assay. The amount of VEGF secreted from the
cells was determined using a human VEGF immunoassay kit (R&D Systems, Minneapolis,
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MN) according to the manufacturer’s instructions. All of the data are presented as the mean ±
standard deviation (SD) of three independent measurements. Statistical analysis was carried
out by a Student’s t test. Statistical significance was assigned for p values <0.05.
Results and Discussion
Nonviral vector delivery of synthetic siRNAs can specifically silence target genes by inducing
mRNA degradation within the cytoplasm.20,21 Unlike DNA delivery systems, which require
nuclear localization, synthetic siRNA delivery systems demand localization to the cytoplasm
for RNAi induction. Localization to the cytoplasm of functional siRNA molecules is an
important step to achieve efficient target gene silencing. Most cationic polymers for gene
delivery, however, condense strongly with nucleic acids and form highly stable polyplexes in
both the extra- and intracellular environment, even after endosomal escape to the cytoplasm.
12 Thus, we hypothesized that bioreducible cationic polymers which degrade in the reductive
environment of the cytoplasm would be more likely to release siRNAs into the cytoplasm,
thereby resulting in enhanced RNA silencing compared to the commercially available cationic
polymer polyethylenimine, bPEI (25 kDa).
We chose to compare our bioreducible cationic polymer, arginine-conjugated poly
(cystaminebisacrylamide-diaminohexane), to bPEI for several reasons. First, bPEI is
considered one of the most successful nonviral gene carriers and is used extensively for in vitro
as well as for in vivo gene delivery due to its high transfection efficiency and reproducibility.
Second, bPEI possesses high endosomal buffering capacity, which facilitates the endosomal
escape of the complexes via the hypothetical proton sponge effect. Third, while several
cholesterol based cationic lipids have been generated as gene carriers and have demonstrated
high transfection efficiency in mammalian cells, most have lacked an effective endosomal
escape mechanism such as that found in bPEI. For all these reasons, as well as its wide
commercial availability, bPEI is still accepted as the gold standard for nonviral, polymer based
gene delivery.
siRNA/poly(CBA-DAH-R) Polyplexes Are Degraded under Reductive Conditions
To develop an efficient siRNA delivery system, we designed a new bioreducible cationic
polymer poly(CBA-DAH-R) containing multiple disulfide linkages in the arginine-modified
polymeric backbone. Poly-(CBA-DAH-R) was prepared by arginine modification after the
synthesis of poly(CBA-DAH) (supplemental figure in the Supporting Information). The
polydisulfide poly(CBA-DAH) was synthesized from the copolymerization of amine donor
1,6-diaminohexane (DAH) to reducible cystaminebisacrylamide (CBA). Then the unprotected
terminal amine group in the backbone of poly(CBA-DAH) was fully modified with L-arginine
(R) to produce poly(CBA-DAH-R). The siRNA polyplex formation and the reductive
degradation of poly-(CBA-DAH-R) were assessed by dynamic light scattering (DLS)
measurements (Figure 1). Poly(CBA-DAH-R) and bPEI were complexed with siRNA
molecules at 200 nm in diameter with a weight ratio of 40:1 and 1:1, respectively. Poly(CBA-
DAH-R) started to condense siRNA at a weight ratio of 10:1, though the polyplexes were not
stabilized until a weight ratio of 20:1. The siRNA/poly(CBA-DAH-R) polyplexes were stably
formed at a few hundred nanometers in size with weight ratios above 20:1. The bioreducible
polycation poly(CBA-DAH-R) spontaneously formed stable nanosized polyplexes with
siRNA molecules due to the electrostatic interactions between the positively charged side-
chain arginine groups of the polymer and the negatively charged phosphate groups of the
siRNAs. DLS analysis showed that the particle size of the siRNA/bPEI polyplexes was
dramatically increased with an increase in the weight ratio, due to significant particle
aggregation of highly positive charged polyplexes (zeta potential over +35 mV). It has been
reported that strongly charged particles are rapidly aggregated under physiologic conditions.
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22 To examine whether the siRNA/poly(CBA-DAH-R) polyplexes degrade and release free
siRNAs under reductive conditions, the siRNA polyplexes with poly(CBA-DAH-R) and bPEI
were preincubated in 2.5 mM DTT solution and the polyplexes were analyzed by DLS. There
was no detectable difference in particle size and surface charge for the siRNA/bPEI polyplexes
with and without DTT treatment (Figure 1b, c). In a reductive environment, however, the size
distribution peaks for the siRNA/poly(CBA-DAH-R) polyplexes at 200 nm particle size
disappeared and the zeta potential was almost neutral (−2.7 ± 0.4 mV) (Figure 1d, e), suggesting
the polyplexes were completely degraded due to the reductive cleavage of the multiple disulfide
linkages in the poly(CBA-DAH-R).
The unique structural characteristics of poly(CBA-DAH-R) were further confirmed in the
electrophoretic mobility shift assay (Figure 2). Poly(CBA-DAH-R) fully condensed siRNA
molecules at weight ratios above 20:1, correlating with the particle formation data determined
by DLS analysis (Figure 1). A reductive environment caused complete siRNA release from
the siRNA/poly(CBA-DAH-R) polyplexes as a result of degradation of the polymers, while
the structure of the siRNA/bPEI polyplexes was not affected by a reductive environment.
Previous studies have shown that polydisulfide polycations exhibit efficient unpackaging of
the polyplexes by the cleavage of disulfide bonds in reductive conditions, which is responsible
for the release of nucleic acids.16–18 The triggered degradation behavior of the siRNA/poly
(CBA-DAH-R) polyplexes increases RNA silencing efficiency by improving the localization
of the siRNA to the cytoplasm.
siRNA/poly(CBA-DAH-R) Polyplexes Decrease Cytotoxicity and Enhance Transfection
Efficiency
To assess the efficacy of poly(CBA-DAH-R) as an siRNA carrier in vitro, the cytotoxic activity
of the siRNA/poly(CBA-DAH-R) polyplexes against PC-3 cells was evaluated by MTT assay
(Figure 3a). The siRNA/poly(CBA-DAH-R) polyplexes had much lower cytotoxicity than the
bPEI formulations. Poly(CBA-DAH-R) exhibited nearly 100% relative cell viability at a
weight ratio up to 40:1, while bPEI showed only 40% relative cell viability at a weight ratio
near 10:1. There was no meaningful difference in cellular toxicity between the unmodified and
the arginine-modified reducible polymers, suggesting that the arginine modification does not
affect the biocompatibility of bioreducible cationic polymers. The cytotoxicity of polycations
is caused by an increase in molecular weight as well as cationic charge density.23 The
cytotoxicity of higher molecular weight polycations, however, decreases with breakdown into
lower molecular weight components.24 Thus, the improved cell viability of poly-(CBA-DAH-
R) may be attributable to its biodegradability. Further in vitro studies conducted at nontoxic
levels of bPEI, poly(CBA-DAH), and poly(CBA-DAH-R) formulations displayed over 90%
cell viability with weight ratios under 1:1, 40:1, and 40:1, respectively.
To investigate the influence of the arginine modification of poly(CBA-DAH-R) on transfection
efficiency, the cellular uptake of fluorescently labeled siRNA formulations by PC-3 cells was
monitored using flow cytometric analysis (Figure 3b). Most of the control and the naked siRNA
treatment groups showed very low fluorescence intensity. However, the fluorescence peaks
for the cells treated with various polyplex formulations were notably shifted to the right. The
percentage of the cells gated from region M for the siRNA/poly(CBA-DAH), siRNA/poly
(CBA-DAH-R), and siRNA/bPEI polyplexes was 57.0%, 81.0% and 88.2%, respectively. The
extent of cellular uptake of the siRNA/poly(CBA-DAH-R) polyplexes was 1.4-fold greater
than that of the siRNA/poly(CBA-DAH) polyplexes. There was no significant difference,
however, between poly(CBA-DAH-R) and bPEI in the cellular uptake of the polyplexes. The
enhanced delivery of the siRNA/poly(CBA-DAH-R) polyplexes is likely due to the arginine
modification of the polydisulfide cationic polymers. Arginine residues, which are rich in
Kim et al. Page 6
Mol Pharm. Author manuscript; available in PMC 2009 September 30.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
membrane translocalization peptides, help enhance the cellular association and membrane
permeability of many biologically active products.19
To assess the potential efficacy of siRNA therapy for cancer, the RNAi activity of the siRNA/
poly(CBA-DAH-R) polyplexes was evaluated in human prostate carcinoma PC-3 cells using
siRNA targeted against VEGF. VEGF has a predominant role in tumor angiogenesis (Figure
3c).25,26 The VEGF siRNA polyplex formulations silenced VEGF gene expression in a
sequence specific manner. Both the siRNA polyplexes with poly(CBA-DAH) and poly(CBA-
DAH-R) decreased VEGF expression. As expected, the arginine-containing polyplexes
showed consistently greater gene silencing efficiency than the unmodified polyplexes,
presumably resulting from the enhanced cellular uptake of the siRNA/poly(CBA-DAH-R)
polyplexes. The VEGF siRNA/poly(CBA-DAH-R) polyplexes formulated at a weight ratio of
40:1 exhibited prominent VEGF silencing activity, compared to the VEGF siRNA/poly(CBA-
DAH) and VEGF siRNA/bPEI (a weight ratio of 1:1) polyplexes. Meanwhile, the VEGF
siRNA/poly(CBA-DAH) polyplexes demonstrated a similar level of VEGF silencing as the
bPEI formulations, though the siRNA/poly(CBA-DAH) polyplexes showed a lower level of
cellular association than the siRNA/bPEI polyplexes (Figure 3b). These results imply that high-
efficiency uptake of siRNA polyplexes does not necessarily guarantee the RNAi activity of
siRNA therapeutics. In addition to enhancing the cellular delivery with arginine modification,
the unique structural characteristic of poly-(CBA-DAH-R) appears to exert considerably more
influence in siRNA-mediated gene silencing compared to other polymer carriers.
Localization to the Cytoplasm of siRNA Molecules by Poly(CBA-DAH-R) Polyplexes Enables
Strong RN-Ai Induction
To verify the hypothesis that reductive degradation of the siRNA/poly(CBA-DAH-R)
polyplexes leads to improved RNA silencing, confocal microscopic observations on
subcellular localization of fluorescein binding siRNA were carried out using PC-3 cells (Figure
4). In the cells transfected by the siRNA/poly(CBA-DAH-R) polyplexes, siRNA was evenly
distributed throughout the cytoplasm. However, the cytoplasmic localization of siRNA was
fully suppressed with the treatment of a glutathione depleting agent, BSO, which is known to
inhibit intracellular reducing potential.27 These findings demonstrate that intact siRNA
molecules were successfully released from the destabilized polyplexes due to the degradation
of the polymer backbones in the reductive environment of the cytoplasm. In contrast, small
fluorescent spots were observed throughout the cells when transfected with the siRNA/bPEI
polyplexes, irrespective of the presence or absence of BSO, suggesting that most of the siRNA
molecules were still complexed in the large bPEI polyplex aggregates due to the limited
degradation of the bPEI polyplexes and release of siRNA at the cellular level. These
observations indicate that the triggered release of siRNA from the siRNA/poly(CBA-DAH-R)
polyplexes could play a critical role in enhancing RNA silencing. To further confirm this
hypothesis, the VEGF gene silencing experiments in the PC-3 cells were conducted under both
reducing and nonreducing conditions (Figure 5a). When the VEGF siRNA/poly(CBA-DAH-
R) polyplexes were transfected in the presence of 10 mM BSO, VEGF expression was
significantly higher, while the bPEI polyplexes exhibited the same level of RNAi activity
against VEGF expression in both BSO treated and BSO untreated cells. These results indicate
that the biodegradability of poly(CBA-DAH-R) increases the localization of siRNA to the
cytoplasm.
VEGF siRNA/poly(CBA-DAH-R) Polyplex Delivery System for the Treatment of Various
Human Carcinomas
The influence of serum proteins upon the VEGF gene silencing activity of the VEGF siRNA/
poly(CBA-DAH-R) polyplexes was evaluated by conducting the transfection under 10% FBS
conditions (Figure 5b). Although both poly(CBA-DAH-R) and bPEI showed approximately a
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2-fold reduction in RNAi activity in the presence of serum proteins, the VEGF siRNA/poly
(CBA-DAH-R) polyplexes still exhibited a higher level of VEGF inhibition compared to the
VEGF siRNA/bPEI polyplexes. These results suggest that the VEGF siRNA/poly(CBA-DAH-
R) polyplex delivery system could be a potential approach for siRNA-based cancer therapy.
To make the VEGF siRNA/poly(CBA-DAH-R) formulation applicable to a wide range of
tumor types, the VEGF gene silencing activity of the VEGF siRNA/poly(CBA-DAH-R)
polyplexes was further assessed in various human cancer cells including oral (KB), cervical
(HeLa), ovarian (A2780), and lung (A549) in addition to the prostate carcinoma PC-3 cells
(Figure 6). The cancer cell lines manifested different levels of VEGF production and VEGF
inhibition by the VEGF siRNA formulations. It is known that cancer cells upregulate VEGF
expression, but the degree of upregulation varies, depending on the cancer cell type.26,28 The
differences in VEGF gene silencing of the VEGF siRNA/poly(CBA-DAH-R) polyplexes in
varied cancer cell types are probably determined by differences in the levels of intracellular
reducing potential, since different cells have different capacities for glutathione synthesis to
maintain the reductive environment of the cytoplasm.29 Poly(CBA-DAH-R) invariably
exhibited higher RNAi activity than bPEI in all cancer cell lines tested, suggesting that the
VEGF siRNA/poly(CBA-DAH-R) polyplex delivery system could be useful in the treatment
of various types of human cancers. To validate the current in vitro study, we are currently
conducting an in vivo study using a human tumor xenograft model, which we anticipate
reporting separately in the near future.
In conclusion, we have demonstrated a new approach for RNAi gene silencing using a VEGF
siRNA/poly(CBA-DAH-R) polyplex delivery system. The siRNA/poly(CBA-DAH-R)
polyplexes successfully localize siRNA to the cytoplasm due to the reductive degradation of
the polymers. In addition to the feature of triggered release, arginine modification of poly
(CBA-DAH-R) enhances cellular permeability, leading to effective down regulation of VEGF
expression in various human cancer cells. Since the siRNA/poly(CBA-DAH-R) polyplex
formulation has low cytotoxicity, high efficiency in target gene silencing, and broad efficacy
in various cell types, the siRNA/poly(CBA-DAH-R) polyplex offers a broad range of potential
applications for delivering therapeutic siRNAs, including cancer, obesity, heart disease, and
diabetes.
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Figure 1.
Particle sizes and surface charges of siRNA/poly(CBA-DAH-R) and siRNA/bPEI polyplexes.
(a) Hydrodynamic diameters of the polyplexes at various weight ratios. Representative size
distribution diagrams and zeta potentials of siRNA/poly(CBA-DAH-R) (b, c) and siRNA/bPEI
(d, e) polyplexes at a weight ratio of 40:1 and 1:1, respectively. In panels (c, e) and (b, d), the
polyplexes were treated with and without 2.5 mM DTT, respectively.
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Figure 2.
Gel retardation assay of siRNA/poly(CBA-DAH-R) polyplexes at various weight ratios
without DTT treatment (a) and with 2.5 mM DTT treatment (b). siRNA/bPEI polyplexes were
formulated at a weight ratio of 1:1.
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Figure 3.
(a) Cellular toxicity assay of poly(CBA-DAH), poly(CBA-DAH-R), and bPEI polyplexes with
siRNA as a function of weight ratio. (b) Representative flow cytometry histograms of PC-3
cells transfected with naked siRNA (green), siRNA/poly(CBA-DAH) (yellow), siRNA/poly
(CBA-DAH-R) (red), and siRNA/bPEI (blue). Cy3-modified siRNA was used. M presents a
gated region (fluorescence intensity (arbitrary unit): 350 – 10,000). (c) VEGF gene silencing
of VEGF siRNA/poly(CBA-DAH-R) polyplexes at various weight ratios. PC-3 cells were
transfected with bPEI (weight ratio 1:1), poly(CBA-DAH), and poly(CBA-DAH-R)
formulations with VEGF siRNA. GFP siRNA/bPEI polyplexes were used as a control.
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Statistical significance, * = p < 0.05 versus bPEI, ** = p < 0.05 versus poly(CBA-DAH). The
VEGF expression was analyzed using an ELISA for human VEGF.
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Figure 4.
Subcellular confocal images of cytoplasmic siRNA release of siRNA/poly(CBA-DAH-R) and
siRNA/bPEI polyplexes with and without glutathione-depleting agent BSO. Cy3-modified
siRNA was used. Scale bars represent 10 μm.
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Figure 5.
(a) Effect of glutathione-depleting agent BSO on VEGF gene silencing of VEGF siRNA/poly-
(CBA-DAH-R) polyplexes in PC-3 cells. Cells were pretreated with or without 10 mM BSO
for 24 h prior to transfection. Statistical significance, * = p < 0.01 versus w/o 10 mM BSO. (b)
Effect of serum proteins on VEGF gene silencing of VEGF siRNA/poly(CBA-DAH-R)
polyplexes in PC-3 cells. Cells were transfected in the media with or without 10% FBS.
Statistical significance, * = p < 0.05 versus bPEI (w/o 10% FBS), ** = p < 0.01 versus bPEI
(w/10% FBS). The amount of VEGF secreted from the cells was determined using an ELISA
for human VEGF.
Kim et al. Page 16
Mol Pharm. Author manuscript; available in PMC 2009 September 30.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 6.
VEGF gene silencing of VEGF siRNA/poly(CBA-DAH-R) polyplexes in various human
cancer cells. Statistically significant difference from bPEI, * = p < 0.05, ** = p < 0.01. The
VEGF expression level was determined using an ELISA for human VEGF.
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